
Release date: 2026-05-22 13:49:07 Article From: Lucius Laos Recommended: 13
Before starting treatment with Alunbrig (brigatinib) and during treatment, you must contact your doctor immediately if you experience any of the following: new or worsening difficulty breathing, chest pain, cough, fever; high blood pressure accompanied by headache or blurred vision; slow pulse causing dizziness or fainting; vision changes such as flashing lights, blurred vision, sensitivity to light; unexplained muscle pain or weakness; severe upper stomach pain that worsens after eating, possibly spreading to the back, with weight loss or nausea; pain on the right side of the abdomen, yellowing of skin or whites of eyes, dark urine; high blood sugar causing thirst, increased urination, hunger, tiredness; and unusual sensitivity of the skin to sunlight. Limit time in the sun during treatment. When outdoors, wear a hat and protective clothing, and use a broad-spectrum sunscreen and lip balm with SPF of at least 30, continuing for at least 5 days after stopping treatment.
Alunbrig may interact with other medicines. You must tell your doctor about all medicines you are using, including prescription drugs, over-the-counter medicines, and herbal products. Pay special attention to the following: antifungal medicines (ketoconazole, itraconazole, voriconazole); anti-HIV drugs (indinavir, nelfinavir, ritonavir, saquinavir); antibiotics (clarithromycin, telithromycin, troleandomycin, nafcillin); antidepressants (nefazodone, St. John's wort); anti-seizure drugs (carbamazepine, phenobarbital, phenytoin); anti-tuberculosis drugs (rifabutin, rifampin); heart medicines (digoxin, quinidine); blood thinners (dabigatran); uric acid lowering drugs (colchicine); cholesterol-lowering drugs (pravastatin, rosuvastatin); immunosuppressants (methotrexate, sulfasalazine, cyclosporine, sirolimus, tacrolimus); as well as modafinil, bosentan, alfentanil, fentanyl, and others. During treatment, avoid eating grapefruit or drinking grapefruit juice, as this can affect blood levels of the medicine.
Females of childbearing potential must use effective non-hormonal contraception during treatment with Alunbrig and for 4 months after the last dose, and avoid becoming pregnant. If you are pregnant or planning to become pregnant, consult your doctor. The medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether brigatinib passes into breast milk. To avoid harm to a nursing infant, do not breastfeed during treatment. Male patients should use effective contraception during treatment and for 3 months after the last dose to avoid causing pregnancy in a partner. This medicine may cause vision problems, dizziness, or tiredness. If you experience these symptoms, do not drive a car or operate machinery. Additionally, this medicine contains lactose; patients with lactose intolerance should consult their doctor. Each tablet contains less than 1 mmol (23 mg) of sodium, essentially sodium-free.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3542025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5532024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3432025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3552025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3302025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3982025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3282025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3032025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643